Jenny Southwood
Adult Health · Madison, ALNPI 1528449816
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 294 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,310, 9.9 times the $336 reported in 2021. Among adult health clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Otsuka America Pharmaceutical, Inc.$538
- Abbott$491
- Lilly USA, LLC$381
- AstraZeneca$331
- Astellas Pharma US Inc$316
- plus $3K from 24 others
What the payments were for
- Food & beverage$5,59498%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 75 | $1,086 |
| Otsuka America Pharmaceutical, Inc. | 28 | $538 |
| Abbott | 16 | $491 |
| Lilly USA, LLC | 21 | $381 |
| AstraZeneca | 16 | $331 |
| Astellas Pharma US Inc | 16 | $316 |
| Pfizer | 16 | $274 |
| Axsome Therapeutics, Inc. | 10 | $224 |
| AbbVie | 7 | $204 |
| GSK | 11 | $202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $196 |
| Amgen | 5 | $190 |
| Inspire Medical Systems, Inc. | 2 | $165 |
| Lundbeck LLC | 9 | $155 |
| Phathom Pharmaceuticals, Inc. | 11 | $133 |
| Exact Sciences | 8 | $123 |
| Boehringer Ingelheim | 7 | $120 |
| Teva Pharmaceuticals USA, Inc. | 1 | $110 |
| Bayer | 5 | $91 |
| Sumitomo Pharma America, Inc. | 4 | $73 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $53 |
| Dynavax Technologies Corporation | 2 | $52 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| Amarin Pharma, Inc. | 2 | $42 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Intra-sana Laboratories | 1 | $14 |
| Merck | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,705 in reported general payments places this provider in the 90th percentile of 308 adult health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 23 | $39,702 |
| RybelsusSemaglutide | 16 | $22,996 |
| TrulicityDulaglutide | 18 | $21,971 |
| MounjaroTirzepatide | 12 | $14,382 |
| JardianceEmpagliflozin | 11 | $12,095 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $2,330 |
| Varenicline Tartrate | 11 | $1,963 |
| Atorvastatin Calcium | 113 | $1,807 |
| SynthroidLevothyroxine Sodium | 18 | $1,749 |
| Levothyroxine Sodium | 123 | $1,462 |
| Rosuvastatin Calcium | 75 | $1,396 |
| Losartan Potassium | 118 | $1,364 |
| Amlodipine Besylate | 197 | $1,271 |
| Pravastatin Sodium | 74 | $1,009 |
| Omeprazole | 73 | $941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,086 | $62,69739 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $381 | $36,35330 claims |
| Boehringer IngelheimJardiance | $120 | $12,09511 claims |
| AbbVieSynthroid | $204 | $1,74918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 adult health providers in Alabama.
Other adult health in Madison
- Kerri AbernathyMadison$4K
- Todd PridmoreMadison$3K
- Wendy CantrellMountain Brk$276K
- Lanier OhareBirmingham$42K
- Jessica WrightBirmingham$33K
- Sara HopperBirmingham$21K
- Andrea SuttonBirmingham$21K
- Olivia ViseHoover$15K
- Lindsay SmithPelham$14K
- Alaina OdomAlabaster$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.